An autopsy study of brains of non-dementia subjects with reported depression during their lifetime suggests that there are discrete neuropathological correlates of late-life depression (Tsopelas et al. Br J Psychiatry 2011; 198: 109-114).
Latest News
Need to re-examine treatment-resistant schizophrenia, clozapine use
March 30, 2011The positioning of the atypical antipsychotic clozapine as a third-line treatment warrants re-examination since this has led to its underutilization in patients with treatment-refractory schizophrenia, according to a new Canadian review (Agid et al. Can J Psychiatry 2010; 55: 677-684).
B cell drug set to enter phase III testing
March 30, 2011Ocrelizumab, a novel anti-CD20 monoclonal antibody, is set to enter phase III testing in MS, according to industry newsletter FierceBiotech (www.fiercebiotech.com). The announcement was made at an investor event hosted by Roche. The drug was developed by Genentech, a subsidiary of Roche, and Biogen Idec.
Dalfampridine may improve walking ability: phase III results
March 9, 2011A phase III trial of dalfampridine, or 4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502).